Incubation:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Quantitative RT-PCR:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Activity Assay:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Luciferase:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Western Blot:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Expressing:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
In Vivo:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
In Vitro:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Sequencing:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Over Expression:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Reporter Assay:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Inhibition:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Transwell Assay:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Transfection:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Migration:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Infection:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Injection:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Immunohistochemistry:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Microarray:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Two Tailed Test:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Real-time Polymerase Chain Reaction:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Derivative Assay:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Construct:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Immunoprecipitation:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Immunofluorescence:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Clinical Proteomics:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Membrane:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Software:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Binding Assay:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Knockdown:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Staining:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Control:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Plasmid Preparation:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Quantitative Proteomics:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Ubiquitin Proteomics:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Lysis:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Produced:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
MTS Assay:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Stable Transfection:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Mutagenesis:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Residue:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Methylation:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
Phospho-proteomics:Article Title: TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
Article Snippet: 4 C. For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence. .. The following antibodies were used: TRAF4 1:2,000 (D1N3A, CST); E-cadherin 1:1,000 (Catalog no. 610181, BD); N-cadherin 1:1,000 (Catalog no. 610920, BD); Vimentin 1:5,000 (CST); SLUG 1:1,000 (C19G7, CST); SNAIL 1:1,000 (C15D3, CST); Flag 1:5,000 (M2, Sigma-Aldrich); phospho-Serine 1:1,000 (612546, BD); SMURF1 1:1,000 (45-K, Santa Cruz Biotechnology); Myc 1:5,000 (9E10, Santa Cruz Biotechnology); HA 1:5,000 (Y11, Santa Cruz Biotechnology); GFP 1:5,000 (FL, Santa Cruz Biotechnology); and GAPDH 1:10,000 (MAB374, Millipore).
Article Title: LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b
Article Snippet: The loading control was β-actin detected on the same blot.The loading control was β-actin detected on the same blot.. The primary antibodies were purchased from Cell Signaling Technology as follows: β-actin (8H10D10), Vimentin (D21H3), E-cadherin (24E10), MMP-2 (D4M2N), MMP-9 (D6O3H), ZEB1 (D80D3), NF-κB p65 (D14E12), Slug (C19G7), TWIST1 (#46702), Snail (C15D3), Phospho-NF-κB p65 (Ser536) (93H1), acetyl-NF-κB p65 (Lys310) (D2S3J), AKT (pan) (C67E7), phospho-AKT Substrate (RXXS*/T*) (110B7E), β-tubulin (9F3), lamin A/C (4C11), TRAF4 (D1N3A), and TRAF5 (D3E2R).
Article Title: TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
Article Snippet: For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.For visualization of protein signals, blots were incubated with secondary antibodies which were HRP-linked and detected using chemiluminescence.. The following antibodies were used: TRAF4 1:2000 (D1N3A, CST), E-cadherin 1:1000 (Cat no. 610181, BD), N-cadherin 1:1000 (Cat no. 610920, BD), Vimentin 1:5000 (CST), SLUG 1:1000 (C19G7, CST), SNAIL 1:1000 (C15D3, CST), Flag 1:5000 (M2, Sigma Aldrich), phospho-Serine 1:1000 (612546, BD), SMURF1 1:1000 (45-K, Santa Cruz), Myc 1:5000 (9E10, Santa Cruz), HA 1:5000 (Y11, Santa Cruz), GFP 1:5000 (FL, Santa Cruz) and GAPDH 1:10,000 (MAB374, Millipore).
|